BioXcel Therapeutics (BTAI) Gains from Investment Securities (2017 - 2026)
BioXcel Therapeutics (BTAI) recorded quarterly Gains from Investment Securities of $330000.0 in Q1 2026, up 340.0% quarter-over-quarter from $75000.0 in Q3 2025, and up 32900.0% on a YoY basis from N/an in Q1 2025.
BioXcel Therapeutics (BTAI) Gains from Investment Securities (2017 - 2026) Analysis & Trends
BioXcel Therapeutics' Gains from Investment Securities history runs 10 years deep, the most recent figure standing at $330000.0 for Q1 2026.
- In Q1 2026, Gains from Investment Securities rose 32900.0% year-over-year to $330000.0; the TTM figure through Mar 2026 stood at $330000.0 (up 9.63% YoY), while the FY2025 annual figure was $15.0, changed 0.0% from the prior year.
- Gains from Investment Securities was $330000.0 for Q1 2026 at BioXcel Therapeutics, up from $75000.0 in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $1.4 million in Q3 2024 to a low of -$343000.0 in Q4 2022.
- Historically, Gains from Investment Securities has averaged $294466.7 across 5 years, with a median of $122000.0 in 2022.
- The sharpest annual moves came in 2025 and 2026: Gains from Investment Securities sank 99.92% in 2025, then jumped 32900.0% in 2026.
- A 5-year view of Gains from Investment Securities shows it stood at -$343000.0 in 2022, then soared by 166.18% to $227000.0 in 2023, then tumbled by 79.74% to $46000.0 in 2024, then soared by 63.04% to $75000.0 in 2025, then jumped by 340.0% to $330000.0 in 2026.
- The last three Gains from Investment Securities figures came in at $330000.0 (Q1 2026), $75000.0 (Q3 2025), and $68000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.77 Bn | 35.04 Bn | 1.97 Bn |
| 2 | Zoetis | 34.11 Bn | 32.16 Bn | 1.62 Bn |
| 3 | United Therapeutics | 23.68 Bn | 21.53 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.48 Bn | 16.40 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.19 Bn | 14.88 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 11.44 Bn | 11.01 Bn | 785.00 Mn |
| 7 | Alkermes | 7.28 Bn | 6.77 Bn | -116.06 Mn |
| 8 | Lantheus Holdings | 6.48 Bn | 5.98 Bn | 230.92 Mn |
| 9 | Hims & Hers Health | 6.35 Bn | 5.60 Bn | 396.79 Mn |
| 10 | BioXcel Therapeutics | 25.81 Mn | 25.81 Mn | -77,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 330,000.00 |
| Mar 31, 2026 | 330,000.00 |
| Sep 30, 2025 | 75,000.00 |
| Sep 30, 2025 | 75,000.00 |
| Jun 30, 2025 | 68,000.00 |
| Jun 30, 2025 | 68,000.00 |
| Mar 31, 2025 | 1,000.00 |
| Mar 31, 2025 | 1,000.00 |
| Dec 31, 2024 | 46,000.00 |
| Dec 31, 2024 | 46,000.00 |
| Sep 30, 2024 | 1.39 Mn |
| Sep 30, 2024 | 1.39 Mn |
| Jun 30, 2024 | 120,000.00 |
| Jun 30, 2024 | 120,000.00 |
| Mar 31, 2024 | 1.20 Mn |
| Mar 31, 2024 | 1.20 Mn |
| Dec 31, 2023 | 227,000.00 |
| Dec 31, 2023 | 227,000.00 |
| Sep 30, 2023 | 905,000.00 |
| Sep 30, 2023 | 905,000.00 |